Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: A cost-effectiveness analysis

Clinical Drug Investigation

Volumn 32, Issue 2, 2012, Pages 73-85

  Brydak, Lidia ^a   Roiz, Julie ^b   Faivre, Pascaline ^b   Reygrobellet, Camille ^c  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b OptumInsight   (France)

^c SANOFI PASTEUR   (France)

Author keywords

Cost effectiveness; Elderly; Immunisation; Influenza virus infections; Influenza virus vaccine; prevention

Indexed keywords

INFLUENZA VACCINE;

AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HEALTH PROGRAM; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MORTALITY; NATIONAL HEALTH INSURANCE; OUTCOME ASSESSMENT; PATHOGEN LOAD; POLAND; PRIORITY JOURNAL; PUBLIC HEALTH; REIMBURSEMENT; SENSITIVITY ANALYSIS;

AGED; COST-BENEFIT ANALYSIS; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INSURANCE COVERAGE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS;

EID: 84855443333     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11594030-000000000-00000     Document Type: Article

References (76)

1. Plotkin SA, Orenstein WA, Offit PA. Inactivated Influenza vaccine. Vaccine. 5 ed. Philadelphis (PA): Saunders Elsevier 2011; 260
2. de Lataillade C, Auvergne S, Delannoy I. 2005 and 2006 seasonal influenza vaccination coverage rates in 10 countries in Africa, Asia Pacific, Europe, Latin America and the Middle East. J Public Health Policy 2009 Apr; 30 (1): 83-101
3. Brydak LB. Influenza: flu pandemic, myth or a real threat [in Polish]? Wyd Rytm Warszawa 2008; 1-492
4. Kardas P, Zasowska A, Dec J, et al. Reasons for low influenza vaccination coverage: cross-sectional survey in Poland. Croat Med J 2011 April; 52 (2): 126-33
5. Blank PR, Schwenkglenks M, Szucs TD. Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons. Infection 2009; 37: 390-400
6. Allsup S, Gosney M, Haycox A, et al. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age. Health Technol Assess 2003; 7 (24): iii-65
7. Allsup SH. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine 2004; 23: 639-45
8. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002 Jun 7; 20 (19-20): 2562-78 (Pubitemid 34615597)
9. Mullooly JP, Bridges CB, Thompson WW, et al. Influenza-and RSV-associated hospitalizations among adults. Vaccine 2007 Jan 15; 25 (5): 846-55
10. Kroneman M, van Essen GA, John PW. Influenza vaccination coverage and reasons to refrain among high-risk persons in four European countries. Vaccine 2006 Jan 30; 24 (5): 622-8 (Pubitemid 43017828)
11. Nitsch-Osuch A, Wardyn K, Choroszi-Krol I. Pneumococcal and influenza vaccine coverage in persons aged above 65 years in 2004-2006 in Poland. Slides presented at the ESWI conference, Poland: 2008
12. Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006; 3: CD004876
13. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994 Dec 7; 272 (21): 1661-5 (Pubitemid 24359136)
14. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007 Oct 4; 357 (14): 1373-81 (Pubitemid 47535592)
15. [No authors listed]. Influenzapandemieplanung: Nationaler Influenzapandemieplan. Bundesgesundheitsblatt-Gesundheitsforschung- Gesundheitsschutz 2005;48:356-390
16. Cartter ML, Renzullo PO, Helgerson SD, et al. Influenza outbreaks in nursing homes: how effective is influenza vaccine in the institutionalized elderly? Infect Control Hosp Epidemiol 1990 Sep; 11 (9): 473-8
17. Deguchi Y, Takasugi Y, Nishimura K. Vaccine effectiveness for influenza in the elderly in welfare nursing homes during an influenza A (H3N2) epidemic. Epidemiol Infect 2000 Oct; 125 (2): 393-7
18. Edmondson Jr WP, Rothenberg R, White PW, et al. A comparison of subcutaneous, nasal, and combined influenza vaccination: II. Protection against natural challenge. Am J Epidemiol 1971 Jun; 93 (6): 480-6
19. Gorse GJ, O'Connor TZ, Young SL, et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003 May 16; 21 (17-18): 2133-44
20. Gravenstein S, Drinka P, Duthie EH, et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 1994 Mar; 42 (3): 245-51 (Pubitemid 24079864)
21. Gross PA, Rodstein M, LaMontagne JR, et al. Epidemiology of acute respiratory illness during an influenza outbreak in a nursing home: a prospective study. Arch Intern Med 1988 Mar; 148 (3): 559-61 (Pubitemid 18085341)
22. Hara M, Sakamoto T, Tanaka K. Effectiveness of influenza vaccination in preventing influenza-like illness among community-dwelling elderly: population-based cohort study in Japan. Vaccine 2006; 24: 5546-51 (Pubitemid 43867104)
23. Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006 Dec 16; 333 (7581): 1241
24. Howarth DM, Chaston TM, Lickiss K, et al. Age-related responses to influenza vaccination in the Newcastle region during 1983 and 1984. Med J Aust 1987 May 18; 146 (10): 514-7 (Pubitemid 17112922)
25. Kawai N, Ikematsu H, Iwaki N, et al. A prospective, internetbased study of the effectiveness and safety of influenza vaccination in the 2001-2002 influenza season. Vaccine 2003 Nov 7; 21 (31): 4507-13 (Pubitemid 37315769)
26. Mangtani P, Cumberland P, Hodgson CR, et al. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004 Jul 1; 190 (1): 1-10 (Pubitemid 38858398)
27. Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001 Jul 15; 154 (2): 155-60 (Pubitemid 32643131)
28. Morens DM, Rash VM. Lessons from a nursing home outbreak of influenza A. Infect Control Hosp Epidemiol 1995 May; 16 (5): 275-80
29. Murasko DM, Bernstein ED, Gardner EM, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002 Jan; 37 (2-3): 427-39 (Pubitemid 34073561)
30. Murayama N, Suzuki H, Arakawa M, et al. Two outbreaks of influenza A (H3N2) in a Japanese nursing home in the winter of 1996-1997, with differing vaccine efficacy. Tohoku J Exp Med 1999 Aug; 188 (4): 289-98
31. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994 Sep 22; 331 (12): 778-84 (Pubitemid 24284768)
32. Nichol KL, Wuorenma J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998 Sep 14; 158 (16): 1769-76 (Pubitemid 28421420)
33. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003 May 16; 21 (17-18): 2216-26 (Pubitemid 36428810)
34. Nicholson KG, Kent J, Hammersley V. Influenza A among community-dwelling elderly persons in Leicestershire during winter 1993-4; cigarette smoking as a risk factor and the efficacy of influenza vaccination. Epidemiol Infect 1999 Aug; 123 (1): 103-8 (Pubitemid 29412861)
35. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005 Feb 18; 23 (13): 1540-8 (Pubitemid 40203391)
36. Ruben FL. Effectiveness of current killed influenza vaccines against influenza A-England-42-72. J Infect Dis 1973 May; 127 (5): 576-7
37. Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts inNovgorod, Russia. J Infect Dis 1993 Oct; 168 (4): 881-7 (Pubitemid 23282559)
38. Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000 Sep 15; 19 (2-3): 308-18 (Pubitemid 30621525)
39. Saito R, Suzuki H, Oshitani H, et al. The effectiveness of influenza vaccine against influenza a (H3N2) virus infections in nursing homes in Niigata, Japan, during the 1998-1999 and 1999-2000 seasons. Infect Control Hosp Epidemiol 2002 Feb; 23 (2): 82-6 (Pubitemid 34205639)
40. Stuart WH, Dull HB, Newton LH, et al. Evaluation of monovalent influenza vaccine in a retirement community during the epidemic of 1965-66. JAMA 1969 Jul 14; 209 (2): 232-8
41. Taylor JL, Dwyer DM, Coffman T, et al. Nursing home outbreak of influenza A (H3N2): evaluation of vaccine efficacy and influenza case definitions. Infect Control Hosp Epidemiol 1992 Feb; 13 (2): 93-7
42. Thompson WW, Shay DK, Weintraub E, et al. Influenzaassociated hospitalizations in the United States. JAMA 2004 Sep 15; 292 (11): 1333-40
43. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 Jan 8; 289 (2): 179-86 (Pubitemid 36068705)
44. Szende A, Nemeth R. Health-related quality of life of the Hungarian population. Orv Hetil 2003 Aug 24; 144 (34): 1667-74
45. British health Survey. Table 5.29: mean EuroQol tariff, by age and sex [online]. Available from URL: http://www.archive. official-documents.co.uk/ document/doh/survey96/tab5-29. htm [Accessed 2011 May 11]
46. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005 Jan; 118 (1): 68-77 (Pubitemid 40082461)
47. Polish pharmacoeconomic society website. 2011 [online]. Available from URL: http://farmakoekonomika.pl/ispor 2011/informacje [Accesssed 2011 Oct 1]
48. US Census Bureau International Database. Population Poland 2009 [online]. Available from URL: http://www.census.gov/population/international/data/idb/ country.php [Accessed 2009 Sep 9]
49. Meier CR, Napalkov PN, Wegmuller Y, et al. Populationbased study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000 Nov; 19 (11): 834-42
50. Irwin DE, Weatherby LB, Huang WY, et al. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res 2001; 1 (1): 8
51. Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics 2001; 19 (3): 293-301 (Pubitemid 32230943)
52. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002 Aug 15; 35 (4): 370-7 (Pubitemid 34852565)
53. GerbierS,Barret B. Assessment of influenza vaccine efficacy/effectiveness in the elderly: Sanofi Pasteur internal report [data on file]. 2007
54. Voordouw BC, van der Linden PD, Simonian S, et al. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. Arch Intern Med 2003 May 12; 163 (9): 1089-94 (Pubitemid 36548938)
55. Schanzer DL, Langley JM, Tam TW. Co-morbidities associated with influenza-attributed mortality, 1994-2000, Canada 14. Vaccine 2008; 26 (36): 4697-703
56. de Andres AL, Garrido PC, Hernandez-Barrera V, et al. Influenza vaccination among the elderly Spanish population: trend from 1993 to 2003 and vaccination-related factors. Eur J Public Health 2007 Jun; 17 (3): 272-7 (Pubitemid 47356293)
57. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995 Oct 1; 123 (7): 518-27
58. Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007 Apr 12; 25 (15): 2842-51 (Pubitemid 46412567)
59. Mazick A, Christiansen AH, Samuelsson S, et al. Using sentinel surveillance to monitor effectiveness of influenza vaccine is feasible: a pilot study in Denmark. Euro Surveill 2006; 11 (10): 254-6
60. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009 Jan 15; 199 (2): 159-67
61. Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; (2): CD001269
62. Vu T, Farish S, Jenkins M, et al. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002 Mar 15; 20 (13-14): 1831-6 (Pubitemid 34242840)
63. Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007 Oct; 7 (10): 658-66 (Pubitemid 47444564)
64. Ortqvist A, Granath F, Askling J, et al. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. Eur RespirJ 2007 Sep;30 (3): 414-22 (Pubitemid 351182062)
65. Groenwold RH, Hoes AW, Hak E. Impact of influenza vaccination on mortality risk among the elderly. Eur Re-spir J 2009 Jul; 34 (1): 56-62
66. Szende A, Williams A. Measuring self-reported population health: an international perspective based on EQ-5D. EuroQoL group Monographs volume 1. Budapest: SpringMed Publishing; 2004
67. Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults. J Gen Intern Med 2003 Oct; 18 (10): 808-15
68. Rothberg MB, Fisher D, Kelly B, et al. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy. Arch Pediatr Adolesc Med 2005 Nov; 159 (11): 1055-62 (Pubitemid 41633366)
69. Jahnz-Rozyk K. Health economic impact of viral respiratory infections and pneumonia diseases on the elderly population in Poland. Merkuriusz Lekarski 2010; 169: 37-40
70. Jahnz-Rozyk K. Pharmaco-economics of anti-influenza vaccinations. Pol Merkur Lekarski 2003 Jun; 14 (84): 679-81
71. Central statistical office. Concise statistical yearbook of Poland-Maly Rocznik Statystyczny polski. 2010 [online]. Available from URL: http://www.stat.gov.pl/bdlen/app/dane-podgrup.hier?p-id=647088&p-token= 268660951 [Accessed 2009 Aug 28]
72. Newall AT, Kelly H, Harsley S, et al. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. Pharmacoeconomics 2009; 27 (6): 439-50
73. Nielen MMJ, Spreeuwenberg P, Paget WJ, et al. The age-specific impact of influenza on hospital admissions and mortality in five countries in Europe. Utrecht: NIVEL; 2010
74. Pradas-Velasco R, Antonanzas-Villar F, Martinez-Zarate MP. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination. Pharmacoeconomics 2008; 26 (1): 45-56
75. Kwong JC, Stukel TA, Lim J, et al. The effect of universal influenza immunization on mortality and health care use 1. PLoS Med 2008 Oct 28; 5 (10): e211
76. World Health Organisation. Guidelines of standardization of economic evaluations of immunization programmes. 2008 [online]. Available from URL: www.who.int/entity/immunization-financing [Accessed 2011 Oct 1]